Although the underlying mechanism needs to be further explored, these findings provide support for the elevated levels of CETN2 and POFUT1 autoantibodies in precancerous lesions and their application in the clinical diagnosis of early ESCC. This evidence concerns the gene CETN2 and esophageal squamous cell carcinoma.